ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Is Up 26.3% After Record DAYBUE Sales and Upgraded 2026 Royalties
In the second quarter of 2026, Neuren Pharmaceuticals reported record DAYBUE net sales of US$125 million, its highest quarterly result since launch, driven by strong uptake of the new DAYBUE STIX powder formulation in the US and supported by positive regulatory progress in Europe.
This sales performance led Neuren to upgrade its full-year 2026 royalty income projections, underscoring how formulation innovation and advancing European approvals are influencing its revenue outlook.
We’ll now...

